516 articles in this topic
Breakthrough antibodies completely prevent EBV infection in lab models, offering hope against virus linked to cancer and chronic disease.
Comprehensive review reveals multiple resistance mechanisms and promising therapeutic approaches to improve outcomes for brain cancer patients.
Mismatch repair-deficient cancers accumulate mutations but respond remarkably well to immune checkpoint inhibitors across tumor types.
New review explores emerging synthetic lethal targets like ATR and WEE1 that could expand precision cancer therapy beyond current PARP inhibitor success.
Groundbreaking study shows PD-1 blockade achieves complete tumor elimination in most mismatch repair-deficient cancers, avoiding surgery.
New study identifies 7-gene signature linking air pollutants to hepatocellular carcinoma prognosis via immune dysfunction.
New research reveals young and elderly cervical cancer patients have completely different molecular signatures requiring age-specific treatments.
STAR-FACS technique enables researchers to isolate and study rare cancer cells with specific mutations, revealing how genetic changes drive tumor behavior.
New research reveals how PD-L1 protein fuels ameloblastoma tumor growth and recurrence, opening doors for targeted therapy approaches.
Researchers develop targeted drug that degrades FTO protein, disrupting ribosome production and protein synthesis in leukemia cells.
Researchers identified three distinct nasopharyngeal cancer subtypes with different treatment vulnerabilities using comprehensive molecular profiling.
Early PSMA upregulation after enzalutamide predicts shorter survival, but adding Lu-177-PSMA-617 improves outcomes in resistant prostate cancer.
